European Commission approves Efmody (hydrocortisone) modified release capsules for treatment of congenital adrenal hyperplasia

This new formulation, given twice daily, has been developed to mimic the physiological 24-hour profile of cortisol. Its benefit compared to standard glucocorticoid therapy is claimed to be its ability to reduce early morning peak of 17-hydroxyprogesterone, a steroid precursor.

Source:

PharmaTimes